查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
脊髓性肌萎缩症治疗市场规模、份额和趋势分析报告：按类型（1or2型）,治疗方法（基因疗法,药物）,药物（Spinraza,Zolgenma）,给药途径,地区细分预测2022-2030年
市场调查报告书
商品编码
1170873

脊髓性肌萎缩症治疗市场规模、份额和趋势分析报告：按类型（1or2型）,治疗方法（基因疗法,药物）,药物（Spinraza,Zolgenma）,给药途径,地区细分预测2022-2030年

Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type (Type1, Type 2), By Treatment (Gene Therapy, Drug), By Drug (Spinraza, Zolgensma), By Route Of Administration, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 95 Pages | 商品交期: 2-10个工作天内

价格

脊髓性肌萎缩症治疗市场的增长和趋势

根据 Grand View Research, Inc. 的一项新研究，到 2030 年，全球脊髓性肌萎缩症治疗市场预计将达到 180 亿美元。 预计从 2022 年到 2030 年，复合年增长率将达到 18.6%。 这种增长可归因于产品批准和发布的增加。 例如，2020 年 8 月，由 Genentech 开发的 Evrysdi（risdiplam）获得美国食品药品监督管理局批准，用于治疗 2 个月及以上儿童患者的脊髓性肌萎缩症（SMA）。

2020 年 5 月，诺华公司还获得欧盟委员会 (EC) 有条件批准 SMA 候选药物 Zolgensma (onasemnogene abeparvovec) 用于治疗 SMA 患者。 它是欧洲唯一批准的基因治疗药物。 2021 年 3 月，PTC Therapeutics 获得了 EMA 的 Evrysdi（risdiplam）上市许可，用于治疗 1 型、2 型和 3 型脊髓性肌萎缩症患者。 因此，预计产品批准数量的增加将推动脊髓性肌萎缩症药物市场的发展。

Novartis AG 通过其全球管理访问计划 (MAP) 为 SMA 患者提供免费药物支持。 该计划向北美、南美、亚洲、澳大利亚、欧洲和非洲等大陆符合条件的 SMA 患者免费提供 100 剂 Zolgensma。 这样，对 Zolgensma 的这种支持计划的存在也加强了促销活动并有助于增加收入。

在全球范围内轻鬆获得 SMA 新生儿筛查和诊断工具应该成为常规方法的一部分。 这将确保早期诊断和及时的 DeepL 治疗。 例如，2021 年 7 月，在北卡罗来纳州教堂山的 UNC 医疗中心，婴儿夏洛特通过早期检查新生儿筛查计划被诊断患有脊髓性肌萎缩症，这是脊髓性肌萎缩症 (SMA) 的里程碑，并接受了基因治疗。 此类筛查计划有望促进疾病的早期诊断和治疗。

此外，製药公司还与研究机构进行了多次大规模合作，以开发治疗脊髓性肌萎缩症患者的新疗法。 例如，2021 年 3 月，PTC Therapeutics, Inc. 和 The Spinal Muscular Atrophy Foundation 开展了一项研究合作，以推进科学研究并开发治疗 SMA 患者的新疗法。

然而，与治疗相关的高成本和用于临床试验目的的参与者人数较少可能会限制预测期内的市场增长。 与孤儿药研发相关的高成本是产品价格上涨的主要因素。 例如，最常用的 SPINRAZA 每次注射成本约为 125,000 美元，每年约 750,000 美元。 此外，Zolgensma (AVXS-101) 每次治疗的费用为 210 万美元。

脊髓性肌萎缩症药物市场报告要点

由于 1 型脊髓性肌萎缩症患者的高患病率和治疗产品的广泛可用性，按产品类型划分，1 型细分市场在 2021 年占据了最大的市场份额

p>

在治疗方面，由于市场渗透率不断提高，基因治疗领域预计在预测期内增长最快。Zolgenma 是唯一在 37 个国家批准用于治疗 SMA 患者的基因疗法。

由于支持性报销政策的存在和产品知名度的提高，2021 年 SPINRAZA 细分市场在药物方面占据主导地位。 SPINRAZA 现在可以在三个欧洲国家完全兑换：意大利、挪威和荷兰。

在给药途径方面，注射剂将在 2021 年主导市场，因为 SMA 患者静脉给药具有高安全性、有效性和耐受性

亚太地区预计在预测期内增长最快。 该地区的增长归因于新产品进入该地区。 例如，2021 年 7 月，F. Hoffmann-La Roche Ltd 在印度推出了用于治疗脊髓性肌萎缩症患者的 Evrysdi（risdiplam）。

内容

第1章调查方法及范围

  • 市场细分
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 初步调查的内容
    • 主要信息列表
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 模型详细信息
    • 商品流分析
      • 方法 1：商品流方法
      • 方法 2：使用自下而上的方法逐个国家/地区进行市场估算
  • 全球市场：CAGR 计算
  • 调查假设
  • 二级信息列表
  • 缩写列表
  • 目的

第 2 章执行摘要

  • 市场概览

第 3 章市场变量、趋势和范围

  • 市场系列展望
    • 母公司的市场前景
  • 监管框架
  • 描绘渗透率和增长前景
  • 管道分析
  • 市场动态
    • 市场驱动因素分析
    • 市场製约因素分析
  • PESTEL 分析

第 4 章全球脊髓性肌萎缩症治疗市场：细分分析，按类型，2018-2030

  • 全球脊髓性肌萎缩症治疗市场：类型变化分析
  • 类型 1
  • 类型 2
  • 类型 3
  • 类型 4

第 5 章全球脊髓性肌萎缩症治疗市场：细分分析，按治疗方式，2018-2030

  • 全球脊髓性肌萎缩症治疗市场：治疗波动分析
  • 基因治疗
  • 医学

第 6 章全球脊髓性肌萎缩症治疗市场：按药物细分分析，2018-2030

  • 全球脊髓性肌萎缩症治疗市场：药物变异分析
  • 斯皮拉扎
  • 佐尔根斯玛 (AVXS-101)
  • 每天
  • 其他

第 7 章全球脊髓性肌萎缩症治疗市场：细分分析，按给药途径，2018-2030

  • 全球脊髓性肌萎缩症治疗市场：给药途径差异分析
  • 口语
  • 注入

第 8 章脊髓性肌萎缩症治疗市场：2018-2030 年各地区细分分析

  • 脊髓性肌萎缩症治疗市场：区域差异分析
    • 北美
      • 美国
      • 加拿大
    • 欧洲
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 意大利
    • 亚太地区
      • 日本
      • 中国
      • 印度
      • 澳大利亚
      • 韩国
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 中东和非洲
      • 南非
      • 沙特阿拉伯
      • 阿拉伯联合酋长国

第 9 章全球脊髓性肌萎缩症治疗市场：竞争分析

  • 主要市场进入者的近期趋势和影响分析
    • 对主要交易和战略联盟的分析
      • 新产品发布
      • 併购
      • 合作伙伴关係和合同
  • 公司分类
    • 创新者
    • 市场领导者
    • 新兴玩家
    • 热图分析
  • 公司市场分析
  • 供应商情况
    • 主要分销商和渠道合作伙伴列表
    • 潜在最终用户列表
    • 2021 年主要参与者的市场份额分析
  • 2021 年公司市场份额
    • 竞争仪表板分析
  • 私人公司
    • 主要初创公司名单
    • 本地网络地图
  • 公司简介
    • 百健
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 诺华公司
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • Ionis Pharmaceuticals Inc.
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • Biohaven 製药公司
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • F. Hoffmann-La Roche Ltd.
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 细胞动力学
      • 公司简介
      • 产品基准
      • 战略举措
    • Scholar Rock, Inc.
      • 公司简介
      • 财务业绩
      • 产品基准
    • PTC 疗法
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • NMD 製药公司
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
Product Code: GVR-2-68038-626-4

Spinal Muscular Atrophy Treatment Market Growth & Trends:

The global spinal muscular atrophy treatment market size is expected to reach USD 18.0 billion by 2030, according to a new study by Grand View Research, Inc. This is expected to expand at a CAGR of 18.6% from 2022 to 2030. This growth can be attributed to the increasing product approval and launches. For instance, in August 2020, the Food and Drug Administration approved Evrysdi (risdiplam) developed by Genentech, Inc., for the treatment of pediatric patients aged two months and older with spinal muscular atrophy (SMA).

In addition, in May 2020, Novartis AG received conditional approval to its SMA candidate Zolgensma (onasemnogene abeparvovec) from the European Commission (EC) to treat patients with SMA. It is only approved gene therapy in Europe. In March 2021, PTC Therapeutics, Inc., received marketing approval for Evrysdi (risdiplam) from the EMA for the treatment of patient with type1, 2, and 3 spinal muscular atrophy. Thus, increasing number of product approvals is expected to drive the spinal muscular atrophy treatment market.

Novartis AG is supporting SMA patients by offering medicine at free of cost through global Managed Access Program (MAP). This program provides 100 doses of Zolgensma at free of charge to eligible SMA patients across continents including North America, South America, Asia, Australia, Europe, and Africa. Thus, presence of such supportive programs for Zolgensma strengthens promotional activities and also aid in generating revenue.

Global SMA newborn screening and easy access to diagnostic tools should be included in routine approach. This would ensure early diagnosis and timely access to treatment. For instance, in July 2021, a charlotte baby received a breakthrough gene therapy treatment for Spinal Muscular Atrophy (SMA) at UNC Medical Center in Chapel Hill, N.C., after diagnosis with spinal muscular atrophy through Early Check newborn screening program. Such screening programs are expected to boost early diagnosis and treatment of disease.

Moreover, there are several extensive research collaborations undertaken by pharmaceutical companies with research institutes for developing novel therapies for the treatment of spinal muscular atrophy patients. For instance, in March 2021, PTC Therapeutics, Inc., and The Spinal Muscular Atrophy Foundation entered into research collaboration to advance scientific research and developing new treatment to treat patients with SMA.

However, high costs associated with the treatment and low availability of participant for clinical trial purposes may restrain market growth over the forecast period. The high cost related to research and development of an orphan drug is a major factor of rising prices of product. For instance, the most commonly used drug Spinraza costs around USD 125,000 per injection and USD 750,000 annually. Furthermore, Zolgensma (AVXS-101) costs USD 2.1 million for one time treatment.

Spinal Muscular Atrophy Treatment Market Report Highlights:

  • By type, the type-1 segment held the largest market share in 2021 due to higher prevalence and wide availability of products for the treatment of patients with type-1 spinal muscular atrophy
  • By treatment, the gene therapy segment is expected to be the fastest growing segment over the forecast period due to increase market penetration. Zolgensma is the only approved gene therapy in 37 countries to treat patient with SMA
  • By drug, the Spinraza segment dominated the market in 2021 due to presence of supportive reimbursement policies and increasing awareness about products. Currently, Spinraza is applicable for full reimbursement in three European countries Italy, Norway, Netherlands
  • By route of administration, the injection segment dominated the market in 2021 due to high safety, efficacy, and tolerability associated with infusion drugs to SMA patients through this route of administration
  • Asia Pacific is expected to be the fastest growing region during the forecast period. The growth of region is attributable to the entry of new products into the region. For instance, in July 2021, F. Hoffmann-La Roche Ltd launched Evrysdi (risdiplam) for the treatment of patient with spinal muscular atrophy in India

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market segmentation
    • 1.1.1 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR'S internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
    • 1.3.6 List of primary sources
  • 1.4 Information or data analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity flow analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Abbreviations
  • 1.11 Objectives
    • 1.11.1 Objective 1
    • 1.11.2 Objective 2
    • 1.11.3 Objective 3
    • 1.11.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
  • 3.2 Regulatory framework
  • 3.3 Penetration and Growth Prospect Mapping
  • 3.4 Pipeline Analysis
  • 3.5 Market Dynamics
    • 3.5.1 Market driver analysis
    • 3.5.2 Market restraint analysis
  • 3.6 PESTEL Analysis

Chapter 4 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 4.1 Global Spinal Muscular Atrophy Treatment Market: Type Movement Analysis
  • 4.2 Type 1
    • 4.2.1 Type 1 market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.3 Type 2
    • 4.3.1 Type 2 market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.4 Type 3
    • 4.4.1 Type 3 market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.5 Type 4
    • 4.5.1 Type 4 market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, by Treatment, 2018 - 2030 (USD Million)

  • 5.1 Global Spinal Muscular Atrophy Treatment Market: Treatment Movement Analysis
  • 5.2 Gene Therapy
    • 5.2.1 Gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3 Drug
    • 5.3.1 Drug market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, By Drug, 2018 - 2030 (USD Million)

  • 6.1 Global Spinal Muscular Atrophy Treatment Market: Drug Movement Analysis
  • 6.2 Spinraza
    • 6.2.1 Spinraza market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3 Zolgensma (AVXS-101)
    • 6.3.1 Zolgensma (AVXS-101) market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4 Evrysdi
    • 6.4.1 Evrysdi market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5 Others
    • 6.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)

  • 7.1 Global Spinal Muscular Atrophy Treatment Market: Route of Administration Movement Analysis
  • 7.2 Oral
    • 7.2.1 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3 Injection
    • 7.3.1 Injection market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Spinal Muscular Atrophy Treatment Market: Segment Analysis, by Region, 2018 - 2030 (USD Million)

  • 8.1 Spinal Muscular Atrophy Treatment Market: Regional Movement Analysis
    • 8.1.1 North America
      • 8.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.1.2 U.S.
      • 8.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.1.3 Canada
      • 8.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.1.2 Europe
      • 8.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.2 U.K.
      • 8.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.3 Germany
      • 8.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.4 France
      • 8.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.5 Spain
      • 8.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.2.6 Italy
      • 8.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.1.3 Asia Pacific
      • 8.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.2 Japan
      • 8.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.3 China
      • 8.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.4 India
      • 8.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.5 Australia
      • 8.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.3.5 South Korea
      • 8.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.1.4 Latin America
      • 8.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.4.2 Brazil
      • 8.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.4.3 Mexico
      • 8.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.4.4 Argentina
      • 8.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.1.5 Middle East & Africa
      • 8.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.5.2 South Africa
      • 8.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.5.3 Saudi Arabia
      • 8.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
      • 8.1.5.5 United Arab Emirates
      • 8.1.5.5.1 United Arab Emirates market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 9 Global Spinal Muscular Atrophy Treatment Market: Competitive Analysis

  • 9.1 Recent Developments and Impact Analysis, by Key Market Participants
    • 9.1.1 Major deals & strategic alliances analysis
      • 9.1.1.1 New Product Launches
      • 9.1.1.2 Mergers and Acquisitions
      • 9.1.1.3 Partnerships & Agreements
  • 9.2 Company Categorization
    • 9.2.1 Innovators
    • 9.2.2 Market Leaders
    • 9.2.3 Emerging Players
    • 9.2.4 Heat Map Analysis
  • 9.3 Company Market Position Analysis
  • 9.4 Vendor Landscape
    • 9.4.1 List of Key Distributors and Channel Partners
    • 9.4.2 List of Potential End Users
    • 9.4.3 Key Company Market Share Analysis, 2021
  • 9.5 Company Market Share, 2021
    • 9.5.1 Competitive Dashboard Analysis
  • 9.6 Private Companies
    • 9.6.1 List of Key Emerging Companies
    • 9.6.2 Regional Network Map
  • 9.7 Company Profiles
    • 9.7.1 Biogen
      • 9.7.1.1 Company overview
      • 9.7.1.2 Financial performance
      • 9.7.1.3 Product benchmarking
      • 9.7.1.4 Strategic initiatives
    • 9.7.2 Novartis AG
      • 9.7.2.1 Company overview
      • 9.7.2.2 Financial performance
      • 9.7.2.3 Product benchmarking
      • 9.7.2.4 Strategic initiatives
    • 9.7.3 Ionis Pharmaceuticals Inc.
      • 9.7.3.1 Company overview
      • 9.7.3.2 Financial performance
      • 9.7.3.3 Product benchmarking
      • 9.7.3.4 Strategic initiatives
    • 9.7.4 Biohaven Pharmaceuticals
      • 9.7.4.1 Company overview
      • 9.7.4.2 Financial performance
      • 9.7.4.3 Product benchmarking
      • 9.7.4.4 Strategic initiatives
    • 9.7.5 F. Hoffmann-La Roche Ltd
      • 9.7.5.1 Company overview
      • 9.7.5.2 Financial performance
      • 9.7.5.3 Product benchmarking
      • 9.7.5.4 Strategic initiatives
    • 9.7.6 Cytokinetics
      • 9.7.6.1 Company overview
      • 9.7.6.2 Product benchmarking
      • 9.7.6.3 Strategic initiatives
    • 9.7.7 Scholar Rock, Inc.
      • 9.7.7.1 Company overview
      • 9.7.7.2 Financial performance
      • 9.7.7.3 Product benchmarking
    • 9.7.8 PTC Therapeutics
      • 9.7.8.1 Company overview
      • 9.7.8.2 Financial performance
      • 9.7.8.3 Product benchmarking
      • 9.7.8.4 Strategic initiatives
    • 9.7.9 NMD Pharma A/S
      • 9.7.9.1 Company overview
      • 9.7.9.2 Financial performance
      • 9.7.9.3 Product benchmarking
      • 9.7.9.4 Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 4 Global Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 5 Global Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 6 Global Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 North America Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 8 North America Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 9 North America Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 11 U.S. Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 13 U.S. Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 15 Canada Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17 Canada Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Canada Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 19 Europe Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 20 Europe Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 21 Europe Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Europe Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 23 Germany Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 24 Germany Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25 Germany Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 26 Germany Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 27 U.K. Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 28 U.K. Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29 U.K. Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 U.K. Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 31 France Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 32 France Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 33 France Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 France Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 35 Italy Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 36 Italy Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 37 Italy Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 Italy Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 39 Spain Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 40 Spain Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 41 Spain Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 Spain Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 47 Japan Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 48 Japan Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 49 Japan Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Japan Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 51 China Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 52 China Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 53 China Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 China Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 55 India Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 56 India Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 57 India Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 India Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 59 South Korea Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 61 South Korea Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 South Korea Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 63 Australia Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 64 Australia Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 65 Australia Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 66 Australia Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 67 Latin America Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 69 Latin America Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 70 Latin America Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 71 Brazil Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 72 Brazil Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 73 Brazil Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 74 Brazil Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 75 Mexico Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 76 Mexico Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 77 Mexico Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 Mexico Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 79 Argentina Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 80 Argentina Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 81 Argentina Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 82 Argentina Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 85 Middle East & Africa Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 86 Middle East & Africa Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 91 South Africa Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 92 South Africa Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 93 South Africa Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 94 South Africa Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 95 UAE Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)
  • Table 96 UAE Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 97 UAE Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 98 UAE Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Spinal Muscular Atrophy Treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Spinal Muscular Atrophy Treatment market snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook, revenue, 2021, (USD Million)
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Spinal muscular atrophy treatment market driver impact
  • Fig. 14 Spinal muscular atrophy treatment market restraint impact
  • Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 16 Industry Analysis - Porter's
  • Fig. 17 Strategy mapping
  • Fig. 18 Spinal muscular atrophy treatment market: Type outlook and key takeaways
  • Fig. 19 Spinal muscular atrophy treatment market: Type movement analysis & market share 2021 & 2030
  • Fig. 20 Type 1 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Type 2 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Type 3 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Type 4 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Spinal muscular atrophy treatment market: Treatment outlook and key takeaways
  • Fig. 25 Spinal muscular atrophy treatment market: Treatment movement analysis & market share 2021 & 2030
  • Fig. 26 Gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Drug market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Spinal muscular atrophy treatment market: Drug outlook and key takeaways
  • Fig. 29 Spinal muscular atrophy treatment market: Drug movement analysis & market share 2021 & 2030
  • Fig. 30 Spinraza market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Zolgensama market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Evrysdi market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Spinal muscular atrophy treatment market : Regional outlook and key takeaways
  • Fig. 35 Regional outlook, 2021 & 2030
  • Fig. 36 North America
  • Fig. 37 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 U.S.
  • Fig. 39 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Canada
  • Fig. 41 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Europe
  • Fig. 43 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 U.K.
  • Fig. 45 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Germany
  • Fig. 47 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 France
  • Fig. 49 France market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Italy
  • Fig. 51 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Spain
  • Fig. 53 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific
  • Fig. 55 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Japan
  • Fig. 57 Japan market estimates and forecast, 2018 - 2030(USD Million)
  • Fig. 58 China
  • Fig. 59 China market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 India
  • Fig. 61 India market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 South Korea
  • Fig. 63 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Australia
  • Fig. 65 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America
  • Fig. 67 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil
  • Fig. 69 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Mexico
  • Fig. 71 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Argentina
  • Fig. 73 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Middle East & Africa
  • Fig. 75 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 South Africa
  • Fig. 77 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Saudi Arabia
  • Fig. 79 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 UAE
  • Fig. 81 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Market differentiators
  • Fig. 83 Key company market share analysis, 2021
  • Fig. 84 Company market position analysis
  • Fig. 85 Competitive dashboard analysis
  • Fig. 86 Regional network map